Upcoming Events
There are no upcoming events available at this time.
Past Events
Jul 20, 2022 at 8:00 AM EDT
Q2 2022 Earnings Call Webcast
Jun 15, 2022 at 9:00 AM EDT
2022 Annual Meeting of Stockholders
May 3, 2022 at 8:00 AM EDT
Q1 2022 Earnings Call Webcast
Mar 28, 2022 at 10:15 AM EDT
Biogen at the Stifel 2022 CNS Days
Mar 7, 2022 at 9:50 AM EST
Biogen at the Cowen 42nd Annual Health Care Conference
Feb 3, 2022 at 8:00 AM EST
Q4 and Full Year 2021 Earnings Call Webcast
Jan 13, 2022 at 8:00 AM EST
Biogen Analyst Q&A Call
View Presentation 852.1 KB
Jan 10, 2022 at 9:45 AM EST
Biogen at the 40th Annual J.P. Morgan Healthcare Conference
Nov 11, 2021 at 5:10 PM EST
Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials at CTAD
View Presentation 778.4 KB
Nov 9, 2021 at 8:00 AM EST
Baseline EMBARK data from EMERGE, ENGAGE, and PRIME participants in the EMBARK re-dosing study at CTAD
View Presentation 425 KB
Oct 20, 2021 at 8:00 AM EDT
Q3 2021 Earnings Call Webcast
Oct 17, 2021 at 4:20 PM EDT
Results from the Phase 3 VALOR study and its open-label extension at ANA 2021
View Presentation 934.2 KB
Sep 21, 2021 at 10:00 AM EDT
Biogen Investor R&D Day
Sep 9, 2021 at 9:30 AM EDT
Biogen at the Morgan Stanley 19th Annual Global Healthcare Conference
Jul 22, 2021 at 8:00 AM EDT
Q2 2021 Earnings Call Webcast
Jun 29, 2021 at 1:50 PM EDT
Biogen to Participate in SVB Leerink’s 3rd Annual CNS Forum
Jun 8, 2021 at 8:00 AM EDT
Biogen ADUHELM Launch Webcast
Biogen ADUHELM Launch 4.3 MB
Jun 2, 2021 at 9:00 AM EDT
2021 Annual Meeting of Stockholders
Apr 22, 2021 at 8:00 AM EDT
Q1 2021 Earnings Call Webcast
Mar 31, 2021
Biogen at the Stifel 3rd Annual CNS Day
Mar 13, 2021
Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD
View Presentation 793.4 KB
Mar 13, 2021
Evaluation of aducanumab efficacy and safety in early Alzheimer’s disease Discussion at AD/PD
Mar 13, 2021
Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD
View Presentation 305.7 KB
Mar 10, 2021
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD
View Presentation 480.1 KB
Mar 10, 2021
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE Discussion at AD/PD
Mar 1, 2021
Biogen at the Cowen 41st Annual Health Care Conference
Feb 23, 2021
Aducanumab data review and Q&A with Global Alzheimer's Platform
View Presentation 2.4 MB
Feb 3, 2021 at 8:00 AM EST
Q4 and Full Year 2020 Earnings Call Webcast
Jan 14, 2021 at 9:00 AM EST
Aducanumab data review and Q&A with Alzheimer's Disease International
View Presentation 2.2 MB
Jan 11, 2021 at 10:00 AM EST
Biogen at the 39th Annual J.P. Morgan Healthcare Conference
Nov 30, 2020 at 9:00 AM EST
Biogen and Sage Collaboration Webcast
Nov 4, 2020 at 10:15 AM EST
Aducanumab EMBARK study design and Q&A at CTAD 2020
View Presentation 751.9 KB
Oct 21, 2020 at 8:00 AM EDT
Q3 2020 Earnings Call Webcast
Biogen Reports Q3 2020 Results 232.7 KB
Sep 23, 2020
Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation replay)
Sep 19, 2020
Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation replay)
View Presentation 795 KB
Sep 14, 2020 at 10:30 AM EDT
Biogen at the Morgan Stanley Virtual Global Healthcare Conference (replay)
Aug 31, 2020
Biogen at the 61st Annual Meeting of the Japanese Society of Neurology (replay)
View Presentation 1.5 MB
Jul 29, 2020 at 7:00 AM CDT
Aducanumab Phase 3 Topline Results at AAIC (encore presentation and Q&A replay)
View Presentation 512.4 KB
Jun 23, 2020 at 12:30 PM EDT
Biogen to Participate in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum (replay)
May 18, 2020
Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation replay)
View Presentation 775.1 KB
May 11, 2020
Biogen at the 2020 World Medical Innovation Forum (replay)
Apr 2, 2020 at 6:00 PM EDT
Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation replay)
View Presentation 1.1 MB
Dec 5, 2019 at 5:00 PM EST
Investor Q&A call following CTAD Presentation (replay)
Dec 5, 2019 at 11:00 AM EST
Aducanumab Phase 3 Topline Results at CTAD (replay)
View Presentation 1.6 MB
Jun 5, 2019 at 8:00 AM EDT
Biogen Webcast on ALS Portfolio (replay)